{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:46:16Z","timestamp":1791884776216,"version":"4.3.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The ratio of sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental growth factor) is an established biomarker for preeclampsia diagnostic triage. GlyFn (glycosylated fibronectin) measured by point-of-care testing is an alternative rapid assessment from finger-stick blood samples. This study was designed to test the hypothesis that the sensitivity of GlyFn is noninferior to that of the sFlt-1\/PlGF ratio in women with suspected preeclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      This prospective observational study evaluated the diagnostic accuracy of both tests for preeclampsia in high-risk participants presenting between 24\n                      <jats:sup>+0<\/jats:sup>\n                      and 36\n                      <jats:sup>+6<\/jats:sup>\n                      weeks of gestation at 5 hospitals from January 2024 to July 2025. Participants underwent simultaneous point-of-care GlyFn testing (Lumella) and laboratory sFlt-1\/PlGF ratio measurements. The primary outcome was birth for preeclampsia within 28 days of testing. Thresholds were set at GlyFn \u2265350 \u03bcg\/mL and sFlt-1\/PlGF ratio \u226538. The noninferiority margin was predefined at 5%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Among 397 participants, 59 (14.9%) had an indicated birth for preeclampsia within 28 days. GlyFn showed a sensitivity of 86.44% (95% CI, 75.02%\u201393.96%) compared with sFlt-1\/PlGF 84.75% (95% CI, 73.01%\u201392.78%). Although sensitivities were numerically similar (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.79), the CI around the difference was too wide to establish noninferiority at the 5% margin. Negative predictive values were 96.40% and 96.59%, respectively. However, GlyFn had a lower specificity (63.31% versus 75.44%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Point-of-care GlyFn testing showed similar sensitivity and negative predictive value to the sFlt-1\/PlGF ratio for predicting an indicated birth for preeclampsia within 28 days. The point-of-care nature of the GlyFn test may facilitate immediate clinical decision-making in diverse healthcare settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>REGISTRATION:<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN13430018\">https:\/\/doi.org\/10.1186\/ISRCTN13430018<\/jats:ext-link>\n                      ; Unique identifier: ISRCTN13430018.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/hypertensionaha.126.27232","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:00:20Z","timestamp":1791882020000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Glycosylated Fibronectin Compared With sFlt-1\/PlGF Ratio for Preeclampsia Assessment"],"prefix":"10.1161","clinical-trial-number":[{"clinical-trial-number":"isrctn13430018","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4961-7398","authenticated-orcid":true,"given":"Nouran","family":"Elbarbary","sequence":"first","affiliation":[{"name":"Fetal Medicine Unit, St George\u2019s University Hospitals NHS Foundation Trust, London, United Kingdom (N.E., B.T., A.B.)."},{"name":"City-St. George\u2019s, University of London, London, United Kingdom (N.E., B.T., A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-0594","authenticated-orcid":true,"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Care and Education, Kingston University, London, United Kingdom (C.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-0716","authenticated-orcid":true,"given":"Ramesh","family":"Ganapathy","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Department, Epsom and St Helier\u2019s University Hospitals NHS Trust, London, United Kingdom (R.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bini","family":"Ajay","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Department, Croydon University Hospitals NHS Trust, London, United Kingdom (B.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Anim-Nyame","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology Department, Kingston University Hospitals NHS Trust, London, United Kingdom (N.A.-N.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-8256","authenticated-orcid":true,"given":"Marcus","family":"Green","sequence":"additional","affiliation":[{"name":"Action on Preeclampsia Charity, Evesham, United Kingdom (M.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9233-4862","authenticated-orcid":true,"given":"Sarah","family":"Fisher","sequence":"additional","affiliation":[{"name":"Katie\u2019s Team Patient-Public Involvement Group, Queen Mary University of London, United Kingdom (S.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5531-4301","authenticated-orcid":true,"given":"Baskaran","family":"Thilaganathan","sequence":"additional","affiliation":[{"name":"Fetal Medicine Unit, St George\u2019s University Hospitals NHS Foundation Trust, London, United Kingdom (N.E., B.T., A.B.)."},{"name":"City-St. George\u2019s, University of London, London, United Kingdom (N.E., B.T., A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2393-7501","authenticated-orcid":true,"given":"Amarnath","family":"Bhide","sequence":"additional","affiliation":[{"name":"Fetal Medicine Unit, St George\u2019s University Hospitals NHS Foundation Trust, London, United Kingdom (N.E., B.T., A.B.)."},{"name":"City-St. George\u2019s, University of London, London, United Kingdom (N.E., B.T., A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semperi.2009.02.010"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70227-X"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00070-7"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313276"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32335-7"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031884"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414838"},{"key":"e_1_3_3_9_2","unstructured":"National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE Guideline [NG133]. Accessed January 25 2026. https:\/\/www.nice.org.uk\/guidance\/ng133"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005532"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10803"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.054361"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33212-4"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2014.07.052"},{"key":"e_1_3_3_15_2","first-page":"S332","article-title":"A novel biomarker, glycosylated fibronectin, for the assessment of preeclampsia.","volume":"206","author":"Nagalla UM","year":"2012","unstructured":"Nagalla UM, Tonita J, Gross GA. A novel biomarker, glycosylated fibronectin, for the assessment of preeclampsia. Am J Obstet Gynecol. 2012;206:S332.","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.29107"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/uog.27458"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012799"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-093586"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003891"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.12739"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1058"},{"key":"e_1_3_3_23_2","first-page":"716","article-title":"Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed pre-eclampsia in women with chronic hypertension.","volume":"56","author":"Sokratous M","year":"2020","unstructured":"Sokratous M, Soothill PW, Chappell LC, Akolekar R, Nicolaides KH. Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed pre-eclampsia in women with chronic hypertension. Ultrasound Obstet Gynecol. 2020;56:716\u2013722.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001525"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003215"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.126.27232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:00:23Z","timestamp":1791882023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.126.27232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":24,"alternative-id":["10.1161\/HYPERTENSIONAHA.126.27232"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.126.27232","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2026-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"HYPERTENSIONAHA.126.27232"}}